Regulation of cancer cell metabolism by hypoxia-inducible factor 1

Seminars in Cancer Biology

Volumn 19, Issue 1, 2009, Pages 12-16

  Semenza, Gregg L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

BNIP3; Glucose transporter; Glycolysis; HIF 1; Lactate dehydrogenase; MCT4; Mitochondrial autophagy; NHE1; Oxygen; PDK1; Warburg effect

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; LACTIC ACID; PYRUVIC ACID; REACTIVE OXYGEN METABOLITE;

CANCER CELL; CELL DEATH; CELL HYPOXIA; CELL METABOLISM; GLUCOSE TRANSPORT; HUMAN; KIDNEY CARCINOMA; METABOLIC REGULATION; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXYGEN TENSION; PH MEASUREMENT; PROTEIN INDUCTION; PROTEIN TARGETING; REVIEW; TUMOR GROWTH;

ANIMALS; CELL HYPOXIA; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS; REACTIVE OXYGEN SPECIES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 60549083256     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2008.11.009     Document Type: Review

References (66)

1. 2 tension. Proc Natl Acad Sci USA 92 (1995) 5510-5514
2. Wang G.L., and Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270 (1995) 1230-1237
3. Manalo D.J., Rowan A., Lavoie T., Natarajan L., Kelly B.D., Ye S.Q., et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105 (2005) 659-669
4. 2 tension. Am J Physiol 271 (1996) C1172-C1180
5. Salceda S., and Caro J. Hypoxia-inducible factor 1α (HIF-1 α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272 (1997) 22642-22647
6. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95 (1998) 7987-7992
7. Kallio P.J., Wilson W.J., O'Brien S., Makino Y., and Poellinger L. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J Biol Chem 274 (1990) 6519-6525
8. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
9. Kamura T., Sato S., Iwai K., Czyzyk-Krzeska M., Conaway R.C., and Conaway J.W. Activation of HIF-1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97 (2000) 10430-10435
10. 2 sensing. Science 292 (2001) 464-468
11. 2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
12. Yu F., White S.B., Zhao Q., and Lee F.S. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA 98 (2001) 9630-9635
13. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001) 43-54
14. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., and Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16 (2002) 1466-1471
15. Vaupel P., and Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26 (2007) 225-239
16. Brizel D.M., Schroeder T., Scher R.L., Walenta S., Clough R.W., Dewhirst M.W., et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 51 (2001) 349-353
17. Koukourakis M.I., Giatromanolaki A., Sivridis E., Gatter K.C., Harris A.L., and Tumour Angiogenesis Research Group. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway-a report of the Tumour Angiogenesis Research Group. J Clin Oncol 24 (2006) 4301-4308
18. Koukourakis M.I., Giatromanolaki A., Bougioukas G., and Sivridis E. Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. Cancer Biol Ther 6 (2007) 1476-1479
19. Fang J.S., Gillies R.D., and Gatenby R.A. Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol 18 (2008) 330-337
20. Kroemer G., and Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13 (2008) 472-482
21. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev 12 (1998) 149-162
22. Kim J.W., Tchernyshyov I., Semenza G.L., and Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3 (2006) 177-185
23. Zhang H., Bosch-Marce M., Shimoda L.A., Tan Y.S., Baek J.H., Wesley J.B., et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 283 (2008) 10892-10903
24. Papandreou I., Cairns R.A., Fontana L., Lim A.L., and Denko N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3 (2006) 187-197
25. Fukuda R., Zhang H., Kim J.W., Shimoda L., Dang C.V., and Semenza G.L. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129 (2007) 111-122
26. Guzy R.D., Hoyos B., Robin E., Chen H., Liu L., Mansfield K.D., et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 1 (2005) 401-408
27. Mansfield K.D., Guzy R.D., Pan Y., Young R.M., Cash T.P., Schumacker P.T., et al. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-α activation. Cell Metab 1 (2005) 393-399
28. Warburg O. The metabolism of tumors (1930), Arnold Constable, London
29. Zhang H., Gao P., Fukuda R., Kumar G., Krishnamachary B., Zeller K.I., et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11 (2007) 407-420
30. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
31. Gao P., Zhang H., Dinavahi R., Li F., Xiang Y., Raman V., et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12 (2007) 230-238
32. Peng Y.J., Yuan G., Ramakrishnan D., Sharma S.D., Bosch-Marce M., Kumar G.K., et al. Heterozygous HIF-1α deficiency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. J Physiol 577 (2006) 705-716
33. Dewhirst M.W., Cao Y., and Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8 (2008) 425-437
34. 2-independent and HSP90 inhibitor-induced degradation of HIF-1α. Mol Cell 25 (2007) 207-217
35. Liao D., and Johnson R.S. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 26 (2007) 281-290
36. Semenza G.L. Vasculogenesis, angiogenesis, and arteriogenesis: mechanisms of blood vessel formation and remodeling. J Cell Biochem 102 (2007) 840-847
37. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 26 (2007) 341-352
38. Semenza G.L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12 (2007) 853-859
39. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004) 391-400
40. Shim H., Dolde C., Lewis B.C., Wu C.S., Dang G., Jungmann R.A., et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 94 (1997) 6658-6663
41. Fantin V.R., St-Pierre J., and Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9 (2006) 425-434
42. Pouysségur J., Dayan F., and Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441 (2006) 437-443
43. Thiry A., Dogné J.M., Masereel B., and Supuran C.T. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 27 (2006) 566-573
44. Cairns R.A., Papandreou I., Sutphin P.D., and Denko N.C. Metabolic targeting of hypoxia and HIF-1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci USA 104 (2007) 9445-9450
45. Baek J.H., Mahon P.C., Oh J., Kelly B., Krishnamachary B., Pearson M., et al. OS-9 interacts with hypoxia-inducible factor 1α and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1α. Mol Cell 17 (2005) 503-512
46. Baek J.H., Liu Y.V., McDonald K.R., Wesley J.B., Hubbi M.E., Byun H., et al. Spermidine/spermine-N1-acetyltransferase 2 is an essential component of the ubiquitin ligase complex that regulates hypoxia-inducible factor 1α. J Biol Chem 282 (2007) 23572-23580
47. Korkolopoulou P., Patsouris E., Konstantinidou A.E., Pavlopoulos P.M., Kavantzas N., Boviatsis E., et al. Hypoxia-inducible factor 1α/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol 30 (2004) 267-278
48. Theodoropoulos V.E., Lazaris A.C., Kastriotis I., Spiliadi C., Theodoropoulos G.E., Tsoukala V., et al. Evaluation of hypoxia-inducible factor 1α overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int 95 (2005) 425-431
49. Theodoropoulos V.E., Lazaris ACh., Sofras F., Gerzelis I., Tsoukala V., Ghikonti I., et al. Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 46 (2004) 200-208
50. Vleugel M.M., Greijer A.E., Shvarts A., van der Groep P., van Berkel M., Aarbodem Y., et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1α expression in invasive breast cancer. J Clin Pathol 58 (2005) 172-177
51. Dales J.P., Garcia S., Meunier-Carpentier S., Andrac-Meyer L., Haddad O., Lavaut M.N., et al. Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 116 (2005) 734-739
52. Giatromanolaki A., Koukourakis M.I., Simopoulos C., and Sivridis E. Metastatic cancer cells from c-erbB-2 negative primary breast cancer maintain the original c-erbB-2/HIF-1α phenotype. Cancer Biol Ther 6 (2007) 153-155
53. Schindl M., Schoppmann S.F., Samonigg H., Hausmaninger H., Kwasny W., Gnant M., et al. Overexpression of hypoxia-inducible factor 1α is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8 (2002) 1831-1837
54. Bos R., van der Groep P., Greijer A.E., Shvarts A., Meijer S., Pinedo H.M., et al. Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97 (2003) 1573-1581
55. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., and Oberhuber G. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60 (2000) 4693-4696
56. Burri P., Djonov V., Aebersold D.M., Lindel K., Studer U., Altermatt H.J., et al. Significant correlation of hypoxia-inducible factor-1α with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 56 (2003) 494-501
57. Bachtiary B., Schindl M., Pötter R., Dreier B., Knocke T.H., Hainfellner J.A., et al. Overexpression of hypoxia-inducible factor 1α indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 9 (2003) 2234-2240
58. Sivridis E., Giatromanolaki A., Gatter K.C., Harris A.L., and Koukourakis M.I. Association of hypoxia-inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95 (2002) 1055-1063
59. Griffiths E.A., Pritchard S.A., Valentine H.R., Whitchelo N., Bishop P.W., Ebert M.P., et al. Hypoxia-inducible factor-1α expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer 96 (2007) 95-103
60. Takahashi R., Tanaka S., Hiyama T., Ito M., Kitadai Y., Sumii M., et al. Hypoxia-inducible factor-1α expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol Rep 10 (2003) 797-802
61. Swinson D.E., Jones J.L., Cox G., Richardson D., Harris A.L., and O'Byrne K.J. Hypoxia-inducible factor-1α in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer 111 (2004) 43-50
62. Giatromanolaki A., Sivridis E., Kouskoukis C., Gatter K.C., Harris A.L., and Koukourakis M.I. Hypoxia-inducible factors 1α and 2α are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 13 (2003) 493-501
63. Birner P., Gatterbauer B., Oberhuber G., Schindl M., Rössler K., Prodinger A., et al. Expression of hypoxia-inducible factor-1α in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92 (2001) 165-171
64. Aebersold D.M., Burri P., Beer K.T., Laissue J., Djonov V., Greiner R.H., et al. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61 (2001) 2911-2916
65. Birner P., Schindl M., Obermair A., Breitenecker G., and Oberhuber G. Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7 (2001) 1661-1668
66. Sun H.C., Qiu Z.J., Liu J., Sun J., Jiang T., Huang K.J., et al. Expression of hypoxia-inducible factor-1α and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol 30 (2007) 1359-1367